newsNew therapy for anaemic myelodysplastic cancer patients1 November 2022 | By Catherine Eckford (European Pharmaceutical Review)Reblozyl, the first erythroid maturation agent showed increased haemoglobin in transfusion-dependant patients with myelodysplastic syndromes.